C-KFDZHaya Therapeutics
RNA-guided therapies, non-coding RNA, cellular reprogramming
reprogrammingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KFDZ
C-KFDZC-KFDZRNA-guided therapies, non-coding RNA, cellular reprogramming
0-100 chain-logic scale · 15 dimensions · scored on public evidence
“Our culture is to deliver on our vision.” For HAYA Therapeutics CEO Samir Ounzain, that vision is urgent and deeply personal. After losing friends and family to chronic diseases he’s determined to change the way the industry approaches them. Not just for HAYA. For everyone. 🎧 Watch the full Careers in Discovery interview with Samir Ounzain now.
From the moment he walked out of a cinema showing Jurassic Park aged 10, Samir Ounzain knew he wanted to work with DNA. That early obsession turned into a career dedicated to understanding the 98% of our genome that doesn’t code for proteins - what’s often referred to as the “dark genome.” In this episode, Samir shares the personal and scientific journey that led to founding HAYA Therapeutics, a Biotech trailblazing an entirely new approach to treating common and chronic diseases. He explains how HAYA builds backwards from unmet patient needs, and forwards with a first-principles view of biology - putting the cell, not the target, at the centre of drug discovery. This is a story about biology, yes - but it’s also about clarity, courage, and commitment to a new model of Biotech.
When asked what he’d change if he built HAYA Therapeutics again, CEO & Co-Founder Samir Ounzain said: “I’d double down on team… and I’d do it earlier.” In this week’s Careers in Discovery, Samir shares how being heavily science-focused in the early days made sense, but he wouldn’t wait as long to bring in translational and development expertise. The result of adding those voices? Faster progress, clearer strategy, and one simple takeaway: it’s never too early to have that input. 🎧 Watch the full episode on Wednesday to hear Samir’s journey, leadership lessons, and advice for Biotech founders.
In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity. The company’s lead candidate, HTX-001, is making progress towards the clinic in cardiomyopathy. CEO Samir is one of the first researchers to publish on lncRNA – which is also known as the Dark Genome. This week, our podcast guest is Samir Ounzain, CEO and co-founder of Haya Therapeutics. Ounzain was one of the first researchers to publish on lncRNA, also known as the ‘dark genome.’ 00:55-03:47: About Haya Therapeutics 03:47-06:37: What is the dark genome? 06:37-09:29: What is the connection between lncRNA and disease? 09:30-13:22: How can disease be addressed via the dark genome? 13:22-16:45: Which diseases are you tackling? 16:45-18:02: What is the EchoHAYA platform? 18:02-21:07: How does your lead candidate, HTX-001, work? 21:07-22:00: Is the objective stopping fibrosis or reversing it? 22:00-23:41: Other comp
Timestamps: 5:22 - From the UK to Switzerland 11:29 - The dark genome and chronic diseases 17:35 - HTX001 and heart failure 26:44 - Sticking to grants at first 34:32 - Managing two separate teams This episode was sponsored by smzh (https://www.smzh.ch/de/kmu) , your independent go-to partner in all matters relating to finance. About Samir Ounzain: Samir Ounzain (https://www.linkedin.com/in/samirounzain/) is the co-founder and CEO of HAYA Therapeutics (https://www.hayatx.com/) , a precision medicines company targeting the regulatory genome for cardiovascular diseases, fibrosis and cancer. He holds a PhD from the University of Leicester and was previously a researcher at Imperial College London, University College London and CHUV Lausanne University Hospital before starting HAYA in 2019, together with his co-founder Daniel Blessing. Early on in his academic career Samir studied the so-called “dark genome” (also known as the “regulatory genome”), whic
#shorts Click here to listen to the full episode: https://buff.ly/3O4riDI About Samir Ounzain: Samir Ounzain is the co-founder and CEO of HAYA Therapeutics, a precision medicines company targeting the regulatory genome for cardiovascular diseases, fibrosis and cancer. He holds a PhD from the University of Leicester and was previously a researcher at Imperial College London, University College London and CHUV Lausanne University Hospital before starting HAYA in 2019, together with his co-founder Daniel Blessing. Early on in his academic career Samir studied the so-called “dark genome” (also known as the “regulatory genome”), which at the time of discovery (2001) was considered “junk DNA”, i.e. the 98% of our DNA that apparently did not make or in any way affect our genes. More recent scientific research has discovered that this regulatory genome is key to understanding how our genes interact with our environment, and can therefore be useful in targeting environment-caused diseases l
#shorts Click here to listen to the full episode: https://buff.ly/3O4riDI About Samir Ounzain: Samir Ounzain is the co-founder and CEO of HAYA Therapeutics, a precision medicines company targeting the regulatory genome for cardiovascular diseases, fibrosis and cancer. He holds a PhD from the University of Leicester and was previously a researcher at Imperial College London, University College London and CHUV Lausanne University Hospital before starting HAYA in 2019, together with his co-founder Daniel Blessing. Early on in his academic career Samir studied the so-called “dark genome” (also known as the “regulatory genome”), which at the time of discovery (2001) was considered “junk DNA”, i.e. the 98% of our DNA that apparently did not make or in any way affect our genes. More recent scientific research has discovered that this regulatory genome is key to understanding how our genes interact with our environment, and can therefore be useful in targeting environment-caused diseases l
#shorts Click here to listen to the full episode: https://buff.ly/3O4riDI About Samir Ounzain: Samir Ounzain is the co-founder and CEO of HAYA Therapeutics, a precision medicines company targeting the regulatory genome for cardiovascular diseases, fibrosis and cancer. He holds a PhD from the University of Leicester and was previously a researcher at Imperial College London, University College London and CHUV Lausanne University Hospital before starting HAYA in 2019, together with his co-founder Daniel Blessing. Early on in his academic career Samir studied the so-called “dark genome” (also known as the “regulatory genome”), which at the time of discovery (2001) was considered “junk DNA”, i.e. the 98% of our DNA that apparently did not make or in any way affect our genes. More recent scientific research has discovered that this regulatory genome is key to understanding how our genes interact with our environment, and can therefore be useful in targeting environment-caused diseases l
About 98 percent of the the human genome consists of non-protein coding regions known as the “dark genome.” Once derided as “junk DNA,” these regions are increasingly understood to play a critical role in the regulation of the genome and offer a novel means of targeting diseases. Haya Therapeutics is exploring long non-coding RNAs as potential therapies to treat a range of diseases. We spoke to Samir Ounzain, co-founder and CEO of Haya, about the dark genome, the potential to use lncRNAs to treat diseases, and its recently announced collaboration with Eli Lily to use Haya’s platform technology to discover therapies for obesity and related metabolic conditions
Salam, j'espère que tu vas bien ! Aujourd'hui, je vais te parler d'un brillant scientifique algérien, qui a fondé l'une des start-up les plus prometteuses de Suisse, et qui pourrait révolutionner le monde de la médecine. 1. Une biotech à la pointe de la technologie. La start-up Haya Therapeutics, fondée et dirigée par un scientifique algérien, multiplie les succès. Début septembre, la société a franchi une étape majeure dans son développement, en signant un gros contrat avec le géant pharmaceutique américain Eli Lilly. Basée à Lausanne, en Suisse, Haya Therapeutics est une biotech suisse qui développe des thérapies programmables guidées par l’ARN, ciblant le génome régulateur pour des maladies graves. La société utilise sa plateforme innovante de modification de l’état cellulaire, pour acquérir de nouvelles connaissances sur la biologie des longs ARN non codants, les caractéristiques de traitement de l’information et le code source du génome obscur. 2. Un Accord à 1 Milliard de Do
Switzerland is the home of excellent deep tech startups, and there is a unique opportunity to discover the best of them at the TOP 100 Swiss Startup Award 2024. What started in 2011 has become a benchmark in Switzerland, including comprehensive activities supporting the TOP 100 Startups. A strong and networked community has come together under the umbrella brand “TOP 100 Startups,” which provides deep insights into the latest proven concepts, strengthens networks, and establishes new business relationships for and with the 553 Swiss deep tech startups that have been featured in the ranking over the past decade. So far, these award-winning startups have created 18,850 jobs and raised CHF 13.6 billion—79 exits, and 9 IPOs top off the achievements of these innovators. The 100 most innovative and promising Swiss startups are picked by a jury of 100 leading investors and startup experts for the 14th consecutive year. The invitation-only Award Night connects the CEOs of the most promising S
Recording of the Boston Epigenetics Society (BES) online meeting February 29, 2024 with Samir Ounzain, Ph.D., CEO and Co-Founder of HAYA Therapeutics. "Unlocking the Regulatory Genome: Pioneering RNA-Guided Therapeutics for Cell-State Modulation in Disease Pathogenesis"
In this episode we are diving deep into the world of the non-coding genome and, more specifically, an exciting new class of biomolecules – the long non-coding RNAs (lncRNA). Welcome Dr. Samir Ounzain, the co-founder and CEO of HAYA Therapeutics. Samir and his startup HAYA are developing first-in-class therapies to target lncRNA responsible for manifestation of various diseases. Samir and HAYA are aiming at fibrosis first, but have in mind a plethora of other conditions that can be treated by their approach. Join us for an insightful conversation on the non-coding genome, journey from basic science to entrepreneurship and the future of precision therapeutics. Together with Samir we discussed: 👉 The founding story of HAYA Therapeutics 👉 The role of non-coding genome in human health 👉 Ability to tweak non-coding genome to treat diseases 👉 Postponing aging using lncRNAs 👉 Impact of on the future of precision medicine 👉 Prerequisites for founding a successful biotec
Dr. Samir Ounzain from HAYA Therapeutics talks about novel RNA therapeutics to treat heart failure. One in five of your friends and family will suffer from heart failure. Why? The current medicines we use are archaic and do not treat the underlying causes of this disease. We have recently found that our genetic junk is full of therapeutic treasure allowing us to silently Wisper new cures to mend broken hearts.
Dr Samir OUNZAIN est l'inventeur de la thérapie génétique pour freiner la fibrose cardiaque suite à un infarctus du myocarde et améliorer la fonction du cœur. Il est fondateur de la start-up "Haya Therapeutics" qui a été primé jeudi 16 Novembre 2017 à Bâle (Suisse) lors du forum international des innovations. Dr Samir OUNZAIN est Algérien, né à Bou-Ismail. ------------------------------------------------------------------------- .
Reprogramming the software of the cell to fight disease Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement View all journals Search Log in Content Explore content About the journal Sign up for alerts RSS feed nature biopharma dealmakers advertisement feature article Reprogramming t
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001 - HAYA Therapeutics Close Navigation Home Approach Pipeline Partnership About Us Careers News Contact Contact Let's work together Lausanne HAYA Therapeutics SA Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland San Diego HAYA Therapeutics Inc 10935 Alexandria Way Suites 101 & 102 San Diego, CA 92121 United States Info [email protected] Jobs [email protected] Press [email protected] Menu Menu Menu Menu Skip to content --> All News HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clini
HAYA Therapeutics Awarded Innosuisse Certificate for Sustainable Growth and Funding - HAYA Therapeutics Close Navigation Home Approach Pipeline Partnership About Us Careers News Contact Contact Let's work together Lausanne HAYA Therapeutics SA Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland San Diego HAYA Therapeutics Inc 10935 Alexandria Way Suites 101 & 102 San Diego, CA 92121 United States Info [email protected] Jobs [email protected] Press [email protected] Menu Menu Menu Menu Skip to content --> All News HAYA Therapeutics Awarded Innosuisse Certificate for Sustainabl … search into using its technology to address cancer. In addition to Innosuisse’s award for HAYA’s potential for growth and success, it is providing 1.5M CHF (approximately $1.64M USD) in non-dilutive funding for HAYA through Innosuisse’s Start-up Innovation Projects, recognizing HAYA’s cutting-edge approach and broad applicability of their long non-coding RNA (lncRNA) platform in developing disease-modifying therapeutics beyond the heart and into oncology. The funds will be us
"> Samir Ounzain – CEO & Scientific Co-Founder, HAYA Therapeutics Search for: Sign in Register Reports Interviews Articles Legal & Regulatory Facts & Figures Op-eds Shop Sunday, June 14, 2026 Sign In Register Home Country Reports All Americas Asia-Pacific Europe Middle East & Africa Exclusive interviews All Latest Americas Asia-Pacific Europe Middle East & Africa Articles All Global Latest Legal & Regulatory All The Pharma Legal Handbook Regulatory, Pricing and Reimbursement Marketing, Manufacturing, Packaging and Labeling Preclinical and Clinical Trials Op-Eds & C
Haya Therapeutics, la biotech lausannoise qui a décroché le milliard avec l’américain Eli Lilly - Le Temps Aller au contenu principal Aller au menu principal Rechercher dans le site Menu Menu Rechercher Epaper Les newsletters Offres d'emploi Édition: CH FR S'abonner Mon compte En continu Iran G7 Mondial 2026 Suisse Monde Économie Opinions Culture Société Sciences Podcasts Vidéos Cyber Fermer le menu Édition Suisse Édition France S'abonner Accueil En continu Iran G7 Mondial 2026 Suisse Monde Économie Opinions Culture Société Sciences Sport Cyber Vidéos Podcasts Data Immobilier Carri … an, elle s’était hissée à la première place du classement Top 100 Swiss Startup Award. Jusqu’à présent, Haya Therapeutics n’avait levé que des fonds d’amorçage à hauteur de 25 millions de dollars. Déjà un compte ? Se connecter Soutenez notre rédaction et accédez à l'intégralité de nos contenus Profitez actuellement de rabais allant jusqu'à -55% sur tous nos abonnements . En profiter! Accès illimité à tous nos contenus sur le site et l'application mobile Édition d
PACTT congratulates CHUV MassChallenge laureates HaYa and Lymphatica | Toggle navigation About PACTT Mission & objectives Our Host Institutions Technologies transferred FAQ Useful links News and Calls Events Researcher Confidentiality Agreement Material Transfer Agreement Collaborate with industry Collaborate with other academic institutions Learn about Intellectual property Disclose an invention or a software Consult Institutional policies Create a start-up company Obtain legal advice Industry Technologies available for licensing Available Competencies Collaborate with researchers Start- … f anti-cancer therapies. Marco Pisano was supported by the spring 2016 InnoTREK grant. PACTT wishes full success to both teams! Useful links : Masschallenge website Le Temps press release Lymphatica website Back to news list PACTT - Technology Transfer Office UNIL-CHUV Rte de la Corniche 9B - CH-1066 Epalinges - +41 21 314 88 86 Contact Us
Haya Therapeutics, la biotech lausannoise qui a décroché le milliard avec l’américain Eli Lilly - Le Temps Aller au contenu principal Aller au menu principal Rechercher dans le site Menu Menu Rechercher Epaper Les newsletters Offres d'emploi Édition: CH FR S'abonner Mon compte En continu Iran G7 Mondial 2026 Suisse Monde Économie Opinions Culture Société Sciences Podcasts Vidéos Cyber Fermer le menu Édition Suisse Édition France S'abonner Accueil En continu Iran G7 Mondial 2026 Suisse Monde Économie Opinions Culture Société Sciences Sport Cyber Vidéos Podcasts Data Immobilier Carri … an, elle s’était hissée à la première place du classement Top 100 Swiss Startup Award. Jusqu’à présent, Haya Therapeutics n’avait levé que des fonds d’amorçage à hauteur de 25 millions de dollars. Déjà un compte ? Se connecter Soutenez notre rédaction et accédez à l'intégralité de nos contenus Profitez actuellement de rabais allant jusqu'à -55% sur tous nos abonnements . En profiter! Accès illimité à tous nos contenus sur le site et l'application mobile Édition d
#100personalities #letemps #swissromand #frenchspeakingswitzerland #ceo #leadership #recognition #leadingimpact #switzerland | HAYA Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cli
Haya Therapeutics SA Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo Haya Therapeutics SA Haya Therapeutics SA Lausanne, Switzerland Watchlist Export About Financials People Deals Funding About Haya Therapeutics SA Company overview Haya Therapeutics SA is a privately-held therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer. Haya Therapeutics SA was founded in 2017 by Daniel Blessing, Samir Ounzain,
Daniel Blessing Haya Therapeutics S.A. [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Merck Appoints Two Life Sciences Leadership Team Members Ona Therapeutics Raises $86.6mSeries B to Advance ADCs DaltonTx Launches Platform and Partners with Sygnature Olix Pharma Secures KRW110b Investment from BOLD and Weiss Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Geno … ger: £15m Biopharma Maintenance Contract in Scotland » More News! » Submit your News! Upcoming Events Goldman Sachs Annual Global Healthcare Conference 2026 Miami World ADC South Korea 2026 Seoul bio:cap Investival 2026 Berlin (BioCap 2026) Swiss Medtech Day 2026 Bern Bio Innovations Europe 2026 The Hague Citi European CEO Healthcare Conference 2026 London ESHG 2026 Göteborg (Gothenburg) DIA 2026 Global Annual Meeting Philadelphia MedTech Summit 2026 Berlin HLTH E … R 2026 Montréal ON Helix 2026 Conference Cambridge » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award - HAYA Therapeutics Close Navigation Home Approach Pipeline Partnership About Us Careers News Contact Contact Let's work together Lausanne HAYA Therapeutics SA Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland San Diego HAYA Therapeutics Inc 10935 Alexandria Way Suites 101 & 102 San Diego, CA 92121 United States Info [email protected] Jobs [email protected] Press [email protected] Menu Menu Menu Menu Skip to content --> All News HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas … ws HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award For Creating a Company Developing an Innovative RNA Therapeutic Approach. Read more Read more Press Release Published on July 1, 2024 First-of-its-kind award recognizes HAYA CEO Samir Ounzain, Ph.D. and CTO Daniel Blessing, Ph.D. for their entrepreneurial vision in life sciences in the DACH region LAUSANNE, Switzerland and SAN DIEGO – July 1, 2024 – HAYA Therapeutics, SA , a company de … iel Blessing have received the inaugural Andreas & Thomas Struengmann Award . HAYA Therapeutic’s Co-Founders Dr. Samir Ounzain, CEO (right) and Dr. Daniel Blessing, CTO received the inaugural Andreas & Thomas Struengmann Award for their entrepreneurial vision in life sciences at the Festival of the Future at the Deutsches Museum in Munich on Friday, June 28, 2024. HAYA Therapeutics is developing RNA-guided programmable precision medicines focused on long no … ces among the DACH region, which includes Germany, Austria and Switzerland, the award honors the efforts of Drs. Ounzain and Blessing in creating a company developing an innovative RNA therapeutic approach targeting lncRNAs for heart disease and a broad range of chronic and underserved conditions. Representatives from the award committee presented the award and the €100,000 cash prize to Drs. Ounzain and Blessing at the Festival of the Future at the Deutsches Museum in Munich … e 28, 2024. “ It is a privilege to receive the Andreas & Thomas Struengmann Award, named to honor two pioneers in the biotech and life sciences industry. We founded HAYA with a mission to bring RNA-based precision medicines to patients with underserved rare and chronic diseases. We are excited for the next phases of HAYA’s growth, especially
HAYA Therapeutics at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - HAYA Therapeutics Close Navigation Home Approach Pipeline Partnership About Us Careers News Contact Contact Let's work together Lausanne HAYA Therapeutics SA Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland San Diego HAYA Therapeutics Inc 10935 Alexandria Way Suites 101 & 102 San Diego, CA 92121 United States Info [email protected] Jobs [email protected] Press [email protected] Menu Menu Menu Menu Skip to content --> All News HAYA Therapeutics at the Annual Meeting of the A
FutureHealth I Die führende Plattform der Gesundheitswirtschaft Schweiz FutureHealth Innovation Challenge Partner NZZ Connect Menu Dr. Daniel Blessing Co-Founder & CTO , HAYA Therapeutics NZZ Connect 2026 Legal information GTC Privacy policy DE EN
Samir Ounzain, HAYA Therapeutics - Careers in Discovery | Podcast on Spotify
Our recent guest and co-founder of HAYA Therapeutics, Samir Ounzain, advises the aspiring #entrepreneurs to introspect themselves and ask two very important questions right at the beginning: 1️⃣ Does my idea solve a real world problem? And if so 👇 2️⃣ Does it do it in a commercially viable way? Find out more in our interview with Samir for the next episode of the Personalized Medicine Podcast: https://www.pmedcast.com/2021/08/11/ep029/ Don’t forget to subscribe to the Personalized Medicine Podcast on your favorite #podcasting platform: 👉 Apple Podcasts: https://lnkd.in/dw6K9Fx 👉 Google Podc
Stream episode RNA-guided programmable therapeutics for fibrosis, Samir Ounzain, CEO & Co-Founder, HAYA Tx by Biotech2050 Podcast podcast | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it RNA-guided programmable therapeutics for fibrosis, Samir Ounzain, CEO & Co-Founder, HAYA Tx by Biotech2050 Podcast published on 2023-05-10T20:05:21Z Synopsis: Samir Ounzain is the CEO and Co-Founder of HAYA Therapeutics, a precision medicines company developing RNA-guided programmable therapeutics targeting
--> Episode 18 | Impulse Podcast top of page Home Episodes About More Use tab to navigate through the menu items. Subscribe! 14.04.2023 #18 Haya Therapeutics Samir Ounzain The dark genome as the next revolution in drug discovery Listen on your favorite platform: Most of our genome does not code for any protein, which led us to believe that 98% of our genetic material was useless. But what was initially termed as the “dark side of the genome” (which Star Wars fans will certainly appreciate ! ) turns out to play a crucial role in modulating our biology. It is in fact th
Samir Ounzain, CEO and co-founder of Haya Therapeutics - A Call to Lead @LifeScience ORG Episode 6 Samir Ounzain, HAYA Therapeutics Published on: 6th November, 2025 How do you lead a company across continents and through uncertainty? In this episode of A Call to Lead , David Kirk speaks with Samir Ounzain, CEO and scientific co-founder of Haya Therapeutics . Samir shares how a lifelong curiosity about how cells “speak” to their environment led him from academia to building a company at the frontier of RNA-guided medicine. He reflects on what it takes to lead through uncertainty, translate visi
Targeting the dark genome to develop new therapies to fight obesity --> details-tag#clickAway keydown.esc@window->details-tag#close:passive" class="group"> Home Episodes About Beyond Biotech - the podcast from Labiotech Home Episodes About + Follow players--transcripts#highlightSegment"> Beyond Biotech - the podcast from Labiotech Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations … utics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity. The company’s lead candidate, HTX-001, is making progress towards the clinic in cardiomyopathy. CEO Samir is one of the first researchers to publish on lncRNA – which is also known as the Dark Genome This week, our podcast guest is Samir Ounzain, CEO and co-founder of Haya Therapeutics. Ounzain was one of the first researchers to publish
News - HAYA Therapeutics Close Navigation Home Approach Pipeline Partnership About Us Careers News Contact Contact Let's work together Lausanne HAYA Therapeutics SA Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland San Diego HAYA Therapeutics Inc 10935 Alexandria Way Suites 101 & 102 San Diego, CA 92121 United States Info [email protected] Jobs [email protected] Press [email protected] Menu Menu Menu Menu Skip to content --> Featured News Upcoming Events All News Follow Us All the News Be part of our journey and stay up to date with our latest announcements. Follow Us Follo
Samir Ounzain, HAYA Therapeuti… — Careers in Discovery — Apple Podcasts Buscar Início Novidades Top charts Buscar 20 de agosto de 2025 47 min Samir Ounzain, HAYA Therapeutics Careers in Discovery Reproduzir From the moment he walked out of a cinema showing Jurassic Park aged 10, Samir Ounzain knew he wanted to work with DNA. That early obsession turned into a career dedicated to understanding the 98% of our genome that doesn’t code for proteins - what’s often referred to as the “dark genome.” In this episode, Samir shares the personal and scientific journey that led to founding HAYA Therapeuti
Leadership Spotlight–Earlybird Health–Samir Ounzain–HAYA | Earlybird Venture Capital LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s U
Haya Therapeutics, la biotech lausannoise qui a décroché le milliard avec l’américain Eli Lilly - Le Temps Aller au contenu principal Aller au menu principal Rechercher dans le site Menu Menu Rechercher Epaper Les newsletters Offres d'emploi Édition: CH FR S'abonner Mon compte En continu Iran G7 Mondial 2026 Suisse Monde Économie Opinions Culture Société Sciences Podcasts Vidéos Cyber Fermer le menu Édition Suisse Édition France S'abonner Accueil En continu Iran G7 Mondial 2026 Suisse Monde Économie Opinions Culture Société Sciences Sport Cyber Vidéos Podcasts Data Immobilier Carri … an, elle s’était hissée à la première place du classement Top 100 Swiss Startup Award. Jusqu’à présent, Haya Therapeutics n’avait levé que des fonds d’amorçage à hauteur de 25 millions de dollars. Déjà un compte ? Se connecter Soutenez notre rédaction et accédez à l'intégralité de nos contenus Profitez actuellement de rabais allant jusqu'à -55% sur tous nos abonnements . En profiter! Accès illimité à tous nos contenus sur le site et l'application mobile Édition d
HAYA Therapeutics' $65M Series A Will Bring LncRNA Targeting Drugs to Clinic | Inside Precision Medicine clinicalomicsprowebdirectory Facebook Linkedin Twitter News Topics Informatics Molecular Dx Patient Care Oncology Precision Medicine Translational Research Magazine Browse Issues Subscribe Subscribe Get Inside Precision Medicine Magazine Get Inside Precision Medicine eNewsletters Multimedia Webinars Summits Podcasts Videos Inside Precision Medicine Live Learning Labs eBooks Search Facebook Linkedin Twitter Sign in Welcome! Log into your account your username your password Forgot your p … nce candidate lncRNAs have been identified and modeled, HAYA primarily looks to apply next-generation ASOs designed for tissue-selective delivery. So far, according to Ounzain, their approach has looked promising in large animal preclinical models, having achieved dose-dependent target engagement in the heart and lungs without exaggerated pharmacology in off-target tissues like the liver or kidneys. This safety profile is critical for translating findings to patients. “Once y
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Samir Ounzain - HAYA Therapeutics | Unlocking the Power of the Dark Genome Digitec Galaxus: Vom 25m²-Büro zum grössten Onlineshop der Schweiz 🎥 Learn Podcast Candid conversations Free Startup Masterclasses Masterclasses by-founders, for-founders Swiss Startup Mafia Map Check out the intricate web of connections between Swiss startups Subscribe to our Newsletter Get updates and access to exclusive startup content Engage Community & Events Connect with Swiss founders Scaleup Circle Operator-led community Syndicate Invest in startups From 5'000 swiss francs Get startup funding From ou … ng Masterclass B2B Sales Masterclass Swisspreneur Blog Community Startup Events Apply to Join the Slack Community Syndicate Startup investments with Swisspreneur Investors: Sign Up for Deals Startups: Apply to Pitch Investment Portfolio About Swisspreneur Team Contact Us Media Kit Subscribe to our Newsletter © Swisspreneur 2024. All rights reserved · Privacy Policy · Contact us Subscribe to our newsletter Get updates and access to exclusive content. We’ll never share your ema
#jpm2025 #innovation #collaboration #hayatherapeutics #haya #regulatorygenome #reprogrammingcells #hayaplatform #lncrna | Daniel Blessing LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking C … iness unit of Chiesi Group, has announced the FDA is considering their New Drug Application for idebenone to treat Leber hereditary optic neuropathy (LHON). A decision could come as early as February 2026. #LHON is a rare inherited mitochondrial disorder, characterized by a sudden loss of central vision. Explore our webpage on therapeutic pipelines to learn more about what’s in development: https://lnkd.in/gGdBKdBv Read the press release here: https://lnkd.in/g43zKsVB 43 1 Co
Haya Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Event … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Haya Therapeutics NEWS JOBS IN THE PRESS NEWS BioSpace ’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets" href="https://www.biospace.com/business/biospaces-nextgen-class-of-2026-attracts-big-bucks-from-tight-wallets" > NextGen BioSpace ’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets From biotech veterans … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® to Accelerate Development of RNA-Guided Therapeutics Platform - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® to Accelerate Development of RNA-Guided Therapeutics Platform June 3, 2025 | 3 min read Twitter LinkedIn Facebook Email Print LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- #Cardiology -- HAYA Therapeutics, SA , a biotechnology … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases May 8, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Series A round led by Sofinnova Partners and Earlybird Venture Capital with syndicate including Eli Lilly a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics Adds Douglas L. Mann, M.D. as Chairperson of Clinical Advisory Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business HAYA Therapeutics Adds Douglas L. Mann, M.D. as Chairperson of Clinical Advisory Board June 20, 2023 | 5 min read Twitter LinkedIn Facebook Email Print HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs, today announced tha … Among his prestigious recognitions, Dr. Mann achieved the Lifetime Achievement Award from the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. He is also Editor-in-Chief of the Journal of the American College of Cardiology: Basic to Translational Science. Dr. Mann holds an M.D. from Temple University School of Medicine and a B.A. in Biology from Lafayette College. Members of HAYA’s Clinical Advisory Board: Douglas Mann … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics Announces Scientific Advisory Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases Al … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business HAYA Therapeutics Announces Scientific Advisory Board August 10, 2021 | 6 min read Twitter LinkedIn Facebook Email Print HAYA Therapeutics today announced the formation and members of its Scientific Advisory Board (SAB). Aug. 10, 2021 12:30 UTC -- Leaders in the fields of RNA and cardi … by several national and international awards, including NIH Directors Innovator Award and Howard Hughes Medical Institute Faculty scholars program. Dr. Rinn was recently considered one of the top 1% influential scientists of the decade by the Web of Science in Genetics and Molecular biology. Christopher Miller, BSc (Hons), MBChB (Hons), PhD, FRCP: Dr. Miller is a cardiologist and cardiovascular researcher in the UK. He leads a heart failure with preserved ejection fraction cl … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards February 16, 2023 | 5 min read Twitter LinkedIn Facebook Email Print HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs, announced … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies May 3, 2022 | 4 min read Twitter LinkedIn Facebook Email Print HAYA Therapeutics, SA announced that Innosuisse, the Swiss Innovation Agency, is supporting two … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis May 20, 2026 | 4 min read Twitter LinkedIn Facebook Email Print HTX-001 is a first-in-class antisense oligonucleotide designed to downregula … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs May 20, 2021 | 5 min read Twitter LinkedIn Facebook Email Print HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long no … eam to bring this technology towards the clinic,” said Mr. Kreitman. “Given our fund’s focus on mechanisms of aging and age-related diseases we already had non-coding RNA aka ‘The Dark Matter of the Genome’ on our radar. We are delighted to partner with leading scientists in this emerging field and are excited to bring efficacious therapeutics tackling age-related fibrosis to patients,” commented Dr. Eckstein. About HAYA Therapeutics HAYA Therapeutics is a precision therapeut … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics to Present on RNA-Guided Regulatory Genome Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FD … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HAYA Therapeutics to Present on RNA-Guided Regulatory Genome Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) May 2, 2025 | 3 min read Twitter LinkedIn Facebook Email Print LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- #ASGCT -- HAYA Therapeutics, SA , a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics at the Swiss Biotech Day Link to X Link to LinkedIn Home Partnering About Press Past events Swiss Biotech Day 2026 Swiss Biotech Day 2025 Swiss Biotech Day 2024 Swiss Biotech Day 2023 Swiss Biotech Day 2022 Swiss Biotech Day 2021 Swiss Biotech Day 2019 Swiss Biotech Day 2018 Swiss Biotech Day 2017 Swiss Biotech Day 2016 Swiss Biotech Day 2015 Swiss Biotech Day 2014 Swiss Biotech Day 2013 Contact Keep me informed FAQ Menu Menu Home Partnering About Press Past events Swiss Biotech Day 2026 Swiss Biotech Day 2025 Swiss Biotech Day 2024 Swiss Biotech Day 2023 Swiss Biotech Day 20
About - HAYA Therapeutics Close Navigation Home Approach Pipeline Partnership About Us Careers News Contact Contact Let's work together Lausanne HAYA Therapeutics SA Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland San Diego HAYA Therapeutics Inc 10935 Alexandria Way Suites 101 & 102 San Diego, CA 92121 United States Info [email protected] Jobs [email protected] Press [email protected] Menu Menu Menu Menu Skip to content --> Story Timeline Team Investors Awards About Us Reprogramming the biology of life with purpose and precision. Learn About HAYA Learn About HAYA The Mean … Daniel Blessing (CTO), he was also awarded the Andreas & Thomas Struengmann Award (2024) for visionary scientific entrepreneurship. Before founding HAYA, Samir was a Project Leader and Research Fellow at Lausanne University Hospital (CHUV), where he led the discovery of hundreds of novel cardiac-enriched lncRNAs, including CARMEN , Meteor , and Wisper —the latter forming the scientific and therapeutic foundation for HAYA’s lead program. Social Media Daniel Blessing Chief … s HAYA’s co-founder he was recognized with the Andreas & Thomas Struengmann Award 2024 for their pioneering entrepreneurial vision. Dr. Blessing’s scientific background includes post-doctoral research at the University Hospital Lausanne (CHUV) in genetic medicines and RNA-targeting therapeutics for the modulation of regulatory genome derive non-coding RNAs and PhD research at the University of Lausanne/EPFL focused on therapeutic gene delivery and gene therapy appro … e more than 20 years ago when she joined Sunstone Capital from her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts. Henrijette is part of several advisory boards including the SUND Advisory Board (University of Copenhagen), The Sanger Venture Advisory Group, and is part of the Invest Europe VC Council. Henrijette holds a combined PhD and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She … rom the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts. Social Media Rabab Nasrallah Partner, Earlybird Rabab joined Earlybird Health – a specialized fund within the broader Earlybird platform – in 2020 and is now a Principal. In addition to her
Daniel Blessing - HAYA Therapeutics | RNA Leaders Europe Speaker You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. 1 - 3 June 2027 Basel, Switzerland Home home Agenda expand_more Agenda Speakers Free Insights expand_more 2025 Winter Wrap up Event Guide Alnylam … s HAYA’s co-founder he was recognized with the Andreas & Thomas Struengmann Award 2024 for their pioneering entrepreneurial vision. Dr. Blessing's scientific background includes post-doctoral research at the University Hospital Lausanne (CHUV) in genetic medicines and RNA-targeting therapeutics for the modulation of regulatory genome derive non-coding RNAs and PhD research at the University of Lausanne/EPFL focused on therapeutic gene delivery and gene therapy approa
Lilly, Haya Ink Potential $1B Drug Discovery Deal to Target Obesity and Metabolic Conditions - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Th … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Lilly, Haya Ink Potential $1B Drug Discovery Deal to Target Obesity and Metabolic Conditions September 4, 2024 | 2 min read | Kate Goodwin Twitter LinkedIn Facebook Email Print External view of Eli Lilly’s world headquarters in Indianapolis iStock, jetcityimage Under a multi-year ag … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HAYA Therapeutics at Pharma Partnering Summit US 2026 | HAYA Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a
HAYA Therapeutics doses first cohort in Phase I HTX-001 trial Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Serv
HAYA Therapeutics | ApexOnco - Clinical Trials news and analysis Skip to main content x Main navigation HOME Content Conferences Data insights Deals Interviews Regulatory Trial results “I am very impressed - it has become my go-to platform” --> Chief Business Officer US public biotech company Click here for more information Search Sign in Breadcrumb Home / HAYA Therapeutics “I am very impressed - it has become my go-to platform” --> Chief Business Officer US public biotech company Click here for more information Subscribe to HAYA Therapeutics Recent Quick take ASCO 2026 – any remai
Pleased to see this work from the HAYA Therapeutics team being presented at AACR. SEAL1 is a novel long non-coding RNA target selectively expressed in pathological myCAFs, a fibroblast cell state… | Samir Ounzain LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at an
HAYA Therapeutics | ApexOnco - Clinical Trials news and analysis Skip to main content x Main navigation HOME Content Conferences Data insights Deals Interviews Regulatory Trial results “I am very impressed - it has become my go-to platform” --> Chief Business Officer US public biotech company Click here for more information Search Sign in Breadcrumb Home / HAYA Therapeutics “I am very impressed - it has become my go-to platform” --> Chief Business Officer US public biotech company Click here for more information Pagination Previous page ‹‹ Page 29 Subscribe to HAYA Therapeutics Rec
HAYA Therapeutics Presents at AACR26 in San Diego | HAYA Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree … ign in Journal of Cancer Metastasis and Treatment (JCMT) 2mo Report this post 🚨Deadline Approaching | Call for Papers Triple-Negative Breast Cancer: From Mechanisms to Translational Frontiers Special Topic in the Journal of Cancer Metastasis and Treatment (JCMT) Triple-negative breast cancer (TNBC) remains one of the most aggressive breast cancer subtypes, characterized by the absence of ER, PR, and HER2 expression and a strong tendency for early recurrence and poor clinical … st Editor: Prof. Gary J. Whitman (MD Anderson Cancer Center, USA) 📅 Submission Deadline: 31 May 2026 (Approaching) We welcome high-quality original research and review articles contributing to advances in TNBC biology and treatment. 🔗 Author Instructions: https://lnkd.in/gHBVmYzC 📥 Submit here: https://lnkd.in/gjcPUMGr #TNBC #TripleNegativeBreastCancer #BreastCancerResearch #Oncology #CancerResearch #Immunotherapy #PrecisionMedicine #TranslationalMedicine #CancerBiology #C
Haya Therapeutics S.A. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Merck Appoints Two Life Sciences Leadership Team Members Ona Therapeutics Raises $86.6mSeries B to Advance ADCs DaltonTx Launches Platform and Partners with Sygnature Olix Pharma Secures KRW110b Investment from BOLD and Weiss Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Genovis Acquires K … ger: £15m Biopharma Maintenance Contract in Scotland » More News! » Submit your News! Upcoming Events Goldman Sachs Annual Global Healthcare Conference 2026 Miami World ADC South Korea 2026 Seoul bio:cap Investival 2026 Berlin (BioCap 2026) Swiss Medtech Day 2026 Bern Bio Innovations Europe 2026 The Hague Citi European CEO Healthcare Conference 2026 London ESHG 2026 Göteborg (Gothenburg) DIA 2026 Global Annual Meeting Philadelphia MedTech Summit 2026 Berlin HLTH E … R 2026 Montréal ON Helix 2026 Conference Cambridge » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
#bio2026 #bio2026 #bio2026 #businessdevelopment #aibiotech #platformtherapeutics #strategicpartnerships #regulatorygenome #corporatedevelopment #valuecreation | HAYA Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept R
HaYa Therapeutics - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Event Directory Exhibitor List Event Map Exhibition Reception BIO Business Solutions® Pavilion Networking Networking at BIO Receptions Exhibitor In-Booth Events Other Events Social Spotlight Events Affiliate Events Application List your event Special Experiences 5K and 1 Mile Course Matchday Lounge Travel Hotel Reservations Book Your Hotel Interactive Hotel Map
#entrepreneurship #lifesciences #innovation #dach #apollohealthventures #hayatherapeutics #awardwinners | Nils Regge LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si … HAYA Therapeutics , for winning the prestigious Andreas & Thomas Strüngmann Award for Entrepreneurship! 🏆 This accolade recognizes HAYA Therapeutics as the most exciting life science company in the DACH region. Our entire team at Apollo Health Ventures is incredibly proud to have been the first institutional investor in Haya Therapeutics. This achievement underscores our commitment to supporting groundbreaking innovations in the life sciences sector. A heartfelt thank yo … sector. A heartfelt thank you to the Athos team for establishing this inspiring award and for the opportunity to connect with so many visionary individuals. Stay tuned for more exciting updates from Apollo Health Ventures and Haya Therapeutics! #Entrepreneurship #LifeSciences #Innovation #DACH #ApolloHealthVentures #HayaTherapeutics #AwardWinners 146 9 Comments Like Comment Share Copy LinkedIn Facebook X Amir R. 1y Report this comment Congrats to you and the entire team Nils,
Usually we like to build companies with Apollo Health Ventures.. But some external investments are too good to say no. The first external deal we did with our fund was Haya Therapeutics. Amazing… | Nils Regge LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any ti … nal investments are too good to say no. The first external deal we did with our fund was Haya Therapeutics. Amazing team, amazing science. Apollo Health Ventures 10,640 followers 1y Our portfolio company, HAYA Therapeutics , is partnering with Eli Lilly and Company to discover new genome targets for obesity and related metabolic conditions, in a deal worth up to $1 billion. By leveraging HAYA’s proprietary RNA platform to target key mechanisms of metabolic diseases, the goal
HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® - HAYA Therapeutics Close Navigation Home Approach Pipeline Partnership About Us Careers News Contact Contact Let's work together Lausanne HAYA Therapeutics SA Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland San Diego HAYA Therapeutics Inc 10935 Alexandria Way Suites 101 & 102 San Diego, CA 92121 United States Info [email protected] Jobs [email protected] Press [email protected] Menu Menu Menu Menu Skip to content --> All News HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® To Accelera
HAYA Therapeutics Announces Collaboration with Lilly - HAYA Therapeutics Close Navigation Home Approach Pipeline Partnership About Us Careers News Contact Contact Let's work together Lausanne HAYA Therapeutics SA Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland San Diego HAYA Therapeutics Inc 10935 Alexandria Way Suites 101 & 102 San Diego, CA 92121 United States Info [email protected] Jobs [email protected] Press [email protected] Menu Menu Menu Menu Skip to content --> All News HAYA Therapeutics Announces Collaboration with Lilly To Discover Novel Regulatory Genome Targe … diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners will identify multiple regulatory genome derived RNA-based drug targets to address these chronic conditions. Under the terms of the collaboration, HAYA will receive an upfront payment, including an equity investment, and is eligible to
HAYA’s Journey - HAYA Therapeutics Close Navigation Home Approach Pipeline Partnership About Us Careers News Contact Contact Let's work together Lausanne HAYA Therapeutics SA Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland San Diego HAYA Therapeutics Inc 10935 Alexandria Way Suites 101 & 102 San Diego, CA 92121 United States Info [email protected] Jobs [email protected] Press [email protected] Menu Menu Menu Menu Skip to content --> All News HAYA’s Journey From Dinosaurs to Torrey Pines. Read more Read more Post Published on February 15, 2022 By Samir Ounzain, PhD , Chief … eek, we raised an additional US$5 million with a seed extension led by Humboldt Fund , which is a team of bold life science investors who are supporting groundbreaking technologies in many industries, including healthcare. Coupled with our initial round announced in May, our total seed round totals almost US$25 million. I am thankful for the continued support from our investors backing our mission of bringing precise and programmable RNA-therapeutics to the market, starting w
Home - HAYA Therapeutics Close Navigation Home Approach Pipeline Partnership About Us Careers News Contact Contact Let's work together Lausanne HAYA Therapeutics SA Rte de la Corniche 5B Batiment Alanine 1066 Epalinges Switzerland San Diego HAYA Therapeutics Inc 10935 Alexandria Way Suites 101 & 102 San Diego, CA 92121 United States Info [email protected] Jobs [email protected] Press [email protected] Menu Menu Menu Menu Skip to content --> Your browser does not support HTML5 videos. Your browser does not support HTML5 videos. Programming Lasting Health RNA-guided therapies built on causal